Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health - Beacon Biosignals
Summary
Beacon Biosignals raised an oversubscribed $86 million Series B to expand its precision medicine data platform and accelerate AI-driven biomarkers for brain health. The company plans to build the world’s largest neurodiagnostic dataset and broaden clinical adoption of its technology. It also highlighted the acquisition and integration of CleveMed’s home sleep-testing technology, which extends its platform beyond EEG into broader cardiopulmonary data. The funding supports Beacon’s work with biopharma partners on diagnostics, patient selection, and CNS drug development.
Funding
Amount
$86.0M
Total raised
Date
November 13, 2025
Announcement date
Investors
Logos Capital, Casdin Capital, Oxford Glycosciences, Indicator Ventures, GV, General Catalyst, Innoviva, Leiras
Lead investors
Company
beaconbiosignals.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected